High-dose cyclophosphamide and rituximab without stem cell transplant: A feasibility study for low grade B-cell, transformed and mantle cell lymphomas

Leukemia and Lymphoma

Volumn 52, Issue 11, 2011, Pages 2076-2081

  Gladstone, Douglas E ^a   Bolaños Meade, Javier ^a   Huff, Carol Ann ^a   Zahurak, Marianna ^b   Flinn, Ian ^c   Borrello, Ivan ^a   Luznik, Leo ^a   Fuchs, Ephraim ^a   Kasamon, Yvette ^a   Matsui, William ^a   Powell, Jonathan ^a   Levitsky, Hyam ^a   Brodsky, Robert A ^b   Ambinder, Richard ^a   Jones, Richard J ^a   Swinnen, Lode J ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c Tennessee Oncology   (United States)

Author keywords

Cyclophosphamide; Mantle cell lymphoma; NHL

Indexed keywords

ANTIEMETIC AGENT; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; MESNA; METHOTREXATE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTHRITIS; ARTICLE; B CELL LYMPHOMA; BACTEREMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DEHYDRATION; DELIRIUM; DISEASE SEVERITY; DRUG FATALITY; DRUG MEGADOSE; EPISTAXIS; EVENT FREE SURVIVAL; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FOLLICULAR LYMPHOMA; HEART ATRIUM FIBRILLATION; HEMATOPOIESIS; HOSPITALIZATION; HUMAN; HYPONATREMIA; HYPOTENSION; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PANCYTOPENIA; PARAINFLUENZA VIRUS INFECTION; PRIORITY JOURNAL; SYNCOPE; TENOSYNOVITIS; THROMBOCYTE TRANSFUSION; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEASIBILITY STUDIES; FEVER; HOSPITALIZATION; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, MANTLE-CELL; MIDDLE AGED; NEOPLASM GRADING; NEUTROPENIA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80054977191     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.594191     Document Type: Article

References (20)

1. Oliansky DM, Gordon LI, King J, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of follicular lymphoma: an evidence-based review. Biol Blood Marrow Transplant 2010;16:443-468.
2. Bierman PJ, Sweetenham JW, Loberiza FR Jr, et al. Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin 's lymphoma: a comparison with allogeneic and autologous transplantation-the Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. J Clin Oncol 2003;21:3744-3753.
3. v an Besien K, Loberiza FR Jr, Bajorunaite R, et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 2003;102:3521-3529.
4. Schouten HC, Qian W, Kvaloy S, et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin 's lymphoma: results from the randomized European CUP trial. J Clin Oncol 2003;21:3918-3927.
5. Montoto S, Canals C, Rohatiner AZ, et al. Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study. Leukemia 2007;21:2324-2331.
6. Emadi A, Jones RJ, Brodsky RA. Cyclophosphamide and cancer: golden anniversary. Nat Rev Clin Oncol 2009;6:638-647.
7. Kaplan E, Meier P. Nonparametric estimator from incomplete observations. J Am Stat Assoc 1958;53:457-481.
8. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719-748.
9. Cox D. Regression models and life tables (with discussion). J R Stat Soc 1972;34:187-220.
10. SAS user 's guide: statistics. Version 5 ed. Cary, NC: SAS Institute, Inc.: 1985.
11. Jones RJ, Gocke CD, Kasamon YL, et al. Circulating clonotypic B cells in classic Hodgkin lymphoma. Blood 2009;113:5920-5926.
12. Matsui W, Wang Q, Barber JP, et al. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res 2008;68:190-197.
13. Hardingham JE, Kotasek D, Sage RE, Dobrovic A, Gooley T, Dale BM. Molecular detection of residual lymphoma cells in peripheral blood stem cell harvests and following autologous transplantation. Bone Marrow Transplant 1993;11:15-20.
14. Gribben JG, Freedman AS, Neuberg D, et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 1991;325: 1525-1533.
15. Kasamon YL, Jones RJ, Gocke CD, et al. Extended follow-up of autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide (4-HC) purging for indolent or transformed non-Hodgkin lymphomas. Biol Blood Marrow Transplant 2011;17:365-373.
16. Dreger P, Rieger M, Seyfarth B, et al. Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcome. Haematologica 2007;92:42-49.
17. Hoerr AL, Gao F, Hidalgo J, et al. Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkin 's lymphoma. J Clin Oncol 2004;22: 4561-4566.
18. Tam CS, Bassett R, Ledesma C, et al. Mature results of the MD Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood 2009;113:4144-4152.
19. Martin P, Chadburn A, Christos P, et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol 2009;27:1209-1213.
20. Geisler CH, Kolstad A, Laurell A, et al. Long-term progressionfree survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008;112:2687-2693.